95120-45-9

Usage

Uses

Used in Pharmaceutical Development:
(2R)-1-methoxy-3-(2-nitro-1H-imidazol-1-yl)propan-2-ol is utilized as a key component in the development of pharmaceutical products due to its potential pharmacological properties. Its unique structure allows it to be a candidate for the creation of new drugs that could address various medical conditions.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (2R)-1-methoxy-3-(2-nitro-1H-imidazol-1-yl)propan-2-ol serves as a subject of study for understanding its interactions with biological targets. This research could lead to the discovery of new mechanisms of action and the development of innovative therapeutic agents.
Used in Biotechnology Applications:
(2R)-1-methoxy-3-(2-nitro-1H-imidazol-1-yl)propan-2-ol may also find use in biotechnology, where its specific chemical features could be employed for targeted drug delivery systems, diagnostic tools, or as part of bioactive molecules with specific functions in biotechnological processes.

Upstream product

• 527-73-1 2-nitro-1H-imidazole 
• 64491-70-9 R(-)-glycidyl methyl ether 

Downstream Products

• 1043483-28-8 TX-2045 

Relevant academic research and scientific papers

Evaluation of (S)- and (R)-misonidazole as GPX inhibitors: Synthesis, characterization including circular dichroism and in vitro testing on bovine GPx-1

Racemic misonidazole, a radiosensitizer formally used in radiation therapy of cancer and to date still applied, was once reported to exhibit strong inhibitory effects on mouse glutathione peroxidases (GPX). This appeared to qualify misonidazole as a lead structure for the development of novel GPX inhibitors to cause oxidative stress in chemotherapy-resistant tumors. A unique feature of misonidazole as an inhibitor of GPX is the absence of a thiol functionality. Therefore, it was expected to selectively target inhibition devoid of promiscuous interactions with cations and sulfhydryl groups. We synthesized the isomers of misonidazole and analyzed the ability of chiroptical high-performance liquid chromatography (HPLC) to identify the particular enantiomers. Due to the chiral pool synthesis, the assignment of the correct configuration could be verified. Finally, we evaluated both isomers for their inhibitory activities on bovine erythrocyte GPx-1, which is 87% homologous to the human enzyme. Despite the previously reported inhibition of racemic misonidazole on the less homologous mouse GPx-1, we did not find any significant inhibitory activity on the bovine enzyme for either isomer. Though misonidazole appears unlikely to be an inhibitor of human GPx-1 activity, we still spotlight misonidazole as a promising fragment-like lead structure in general. The (S)- and (R)-isomers of misonidazole were synthesized and analyzed for their inhibitory activities on bovine erythrocyte GPx-1, which is 87% homologous to the human enzyme. Although misonidazole was found to be not likely to be an inhibitor of human GPx-1 activity, misonidazole is still spotlighted as a promising fragment-like lead structure in general.

Angiogenesis inhibitor TX-1898: Syntheses of the enantiomers of sterically diverse haloacetylcarbamoyl-2-nitroimidazole hypoxic cell radiosensitizers

(R)- and (S)-Epichlorohydrins were used to prepare the enantiomers of sterically diverse haloacetylcarbamoyl-2-nitroimidazoles that function as hypoxic cell radiosensitizers. The synthetic design allowed for introduction of a side chain of varying bulk th